Results 121 to 130 of about 87,565 (266)

Complications of Intravenous Midazolam–Fentanyl Sedation in Children and Adults Undergoing Oral Surgery: A Retrospective Study [PDF]

Margaux Nys, Melisa Garip, Ruxandra Coropciuc, Jan Meeus, Paul Legrand, Constantinus Politis   +5 more
openalex   +1 more source

Behavioural Effects and Naloxone Effectiveness With New Synthetic Opioids

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction The global drug market has seen an emergence of potent synthetic opioids, including benzimidazole‐derived substances known as nitazenes. These compounds have been implicated in fatal and non‐fatal overdoses. This review aims to synthesise current evidence on the pharmacological effects, potency and naloxone responsiveness of new ...
Suzanne Nielsen, João Pedro Silva, Jermaine D. Jones, Alex Krotulski, Dilkushi Poovendran, Deusdedit Muzangizi, Gilles Forte, Jason White, Sandra D. Comer   +8 more
wiley   +1 more source

Overdose Deaths Involving Fentanyl and Fentanyl Analogs — New York City, 2000–2017 [PDF]

, 2019
Cody Colon-Berezin, Michelle L. Nolan, Jaclyn Blachman-Forshay, Denise Paone   +3 more
openalex   +1 more source

Is Addiction Research Addicted to Artificial Intelligence? Mapping the Intersection of Artificial Intelligence, Substance Use and Mental Health Through a Bibliometric Analysis

Drug and Alcohol Review, EarlyView.
ABSTRACT Issues From extracting insights from large‐scale, multimodal data to prevention and support, there is growing interest in the applications and implications of recent advances in Artificial Intelligence (AI) within the fields of addiction, substance use and mental health, which we refer to as ASUM.
Loïs Vanhée, Simone Scarpa
wiley   +1 more source

A Comparison of Lignocaine 2% with Adrenaline 1:200,000 and Lignocaine 2% with Adrenaline 1:200,000 plus Fentanyl as Agents for Caudal Anaesthesia in Children Undergoing Circumcision [PDF]

, 1990
R. D. M. Jones, W. M. S. Gunawardene, C. K. Yeung   +2 more
openalex   +1 more source

Community Pharmacy‐Based Injectable Opioid Agonist Treatment: Findings From a Canadian Pilot Program

Drug and Alcohol Review, EarlyView.
ABSTRACT Introduction Access to evidence‐based treatment for opioid use disorder remains limited, particularly for individuals who have not responded to oral opioid agonist treatment (OAT). A community pharmacy‐based model of injectable OAT (iOAT) was piloted in Vancouver, Canada from March 2017 to December 2018. This brief report describes the program
Tamara Mihic, Maria Eugenia Socias, Karen McCrae, Cheyenne Johnson, Seonaid Nolan, Cameron Grant, Christy Sutherland, Nadia Fairbairn   +7 more
wiley   +1 more source

A Novel and Validated GC-MS/MS Method for the Detection of Four Opioids and Seven Fentanoids in Oral Fluid for Forensic Applications. [PDF]

Molecules
Tittarelli R, Filardi D, Mineo F, Mannocchi G.   +3 more
europepmc   +1 more source

COMPARISON OF FENTANYL TO THIOPENTAL AND PROPOFOL FOR MAINTENANCE OF ANESTHESIA DURING CARDIAC SURGERY [PDF]

, 1988
Cristina Mora, Carolyn Dudek, Richard H. Epstein, Marc C. Torjman, P. F. White   +4 more
openalex   +1 more source

A closer look at Doleac and Mukherjee (2022) and the effects of naloxone access laws on opioid ER admissions

Economic Inquiry, EarlyView.
Abstract In their 2022 study, ‘The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime,’ Doleac and Mukherjee conclude that broadening access to a life‐saving drug—naloxone—does not reduce opioid‐related mortality as the drug simultaneously encourages riskier drug use. I show issues with their data, design, and estimation methods. For
Sergey Alexeev
wiley   +1 more source

Is Fentanyl Rebound an Intrinsic Feature of Naloxone Reversal? [PDF]

Pharmaceuticals (Basel)
Voronkov M, Nikonov G, Uzbil M, Milevich G, Abernethy J, Barthélémy I.   +5 more
europepmc   +1 more source